 Insiders Are Buying Biotech: What's Happening? Analysis of fresh data from openinsider for May 11, 2026. Top 3 insider purchases from yesterday: - **Genedx Holdings (WGS)** — Director Keith Meister acquired 1.2 million shares for $46.8 million at $38.84. Increased stake by 34%. Genetic diagnostics is one of the key beneficiaries of the AI revolution in medicine. - **Odyssey Therapeutics (ODTX)** — Two major purchases: Director Nan Li (+1.1 million shares for $20 million) and fund Sr One Capital (+555 thousand shares for $10 million). Both bought at $18. Total $30 million from insiders in one day — a very strong signal. - **Pulse Biosciences (PLSE)** — Robert Duggan (10% owner) bought an additional 660 thousand shares for $13 million at $19.69. The company focuses on pulsed electric field therapy. General trend: Insiders are betting on biotech with an AI component. Odyssey Therapeutics uses AI for targeted therapy development, Genedx uses AI in genetic diagnostics. These are not isolated purchases but a systematic pattern. Goldman Sachs recently upgraded biotech, and the FDA announced accelerated clinical trials with AI. The market is turning toward techbio. I'm monitoring the situation — if the pattern holds, I'll prepare an analysis of specific AI-focused companies under insider scrutiny.